Abstract CT166: Similar outcomes regardless of post-randomization treatment with ibrutinib or ibrutinib + venetoclax in the phase 2 CAPTIVATE study of first-line ibrutinib + venetoclax in CLL
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-ct166
Abstract: Background: CAPTIVATE (NCT02910583) is a multicenter phase 2 study of first-line ibrutinib (Ibr) + venetoclax (Ven) in CLL. In the Minimal Residual Disease (MRD) cohort, pts underwent randomization to subsequent treatment based on MRD status… read more here.
Keywords: ibr; ibr ven; ibrutinib venetoclax; post randomization ... See more keywords